Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 9/2014

01-09-2014 | Original Article

Bone marrow mesenchymal stromal cells affect the cell cycle arrest effect of genotoxic agents on acute lymphocytic leukemia cells via p21 down-regulation

Authors: Yiran Zhang, Kaimin Hu, Yongxian Hu, Lizhen Liu, Binsheng Wang, He Huang

Published in: Annals of Hematology | Issue 9/2014

Login to get access

Abstract

The effect of bone marrow microenvironment on the cell cycle of acute lymphocytic leukemia (ALL) and the underlying mechanism has not been elucidated. In this study, we found that in normal condition, bone marrow mesenchymal stromal cells (BM-MSCs) had no significant effect on the cell cycle and apoptosis of ALL; in the condition when the cell cycle of ALL was blocked by genotoxic agents, BM-MSCs could increase the S-phase cell ratio and decrease the G2/M phase ratio of ALL. Besides, BM-MSCs could protect ALL cells from drug-induced apoptosis. Then, we proved that BM-MSCs affect the cell cycle arrest effect of genotoxic agents on ALL cells via p21 down-regulation. Moreover, our results indicated that activation of Wnt/β-catenin and Erk pathways might be involved in the BM-MSC-induced down-regulation of p21 in ALL cells. Targeting microenvironment-related signaling pathway may therefore be a potential novel approach for ALL therapy.
Literature
1.
2.
Fielding AK, Richards SM, Chopra R et al (2007) Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 109(3):944–950PubMedCrossRef
3.
Colmone A, Amorim M, Pontier AL, Wang S, Jablonski E, Sipkins DA (2008) Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 322(5909):1861–1865PubMedCrossRef
4.
Tesfai Y, Ford J, Carter KW et al (2012) Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy. Leuk Res 36(3):299–306PubMedCrossRef
5.
6.
Gaundar SS, Bradstock KF, Bendall LJ (2009) p38MAPK inhibitors attenuate cytokine production by bone marrow stromal cells and reduce stroma-mediated proliferation of acute lymphoblastic leukemia cells. Cell Cycle 8(18):2975–2983PubMedCrossRef
7.
Scupoli MT, Donadelli M, Cioffi F et al (2008) Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-kappaB and JNK/AP-1 pathways. Haematologica 93(4):524–532PubMedCrossRef
8.
Juarez J, Dela Pena A, Baraz R et al (2007) CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia 21(6):1249–1257PubMedCrossRef
9.
Juarez J, Baraz R, Gaundar S, Bradstock K, Bendall L (2007) Interaction of interleukin-7 and interleukin-3 with the CXCL12-induced proliferation of B-cell progenitor acute lymphoblastic leukemia. Haematologica 92(4):450–459PubMedCrossRef
10.
O'Leary H, Akers SM, Piktel D et al (2010) VE-cadherin regulates Philadelphia chromosome positive acute lymphoblastic leukemia sensitivity to apoptosis. Cancer Microenviron 3(1):67–81PubMedCentralPubMedCrossRef
11.
Wang L, O'Leary H, Fortney J, Gibson LF (2007) Ph+/VE-cadherin + identifies a stem cell like population of acute lymphoblastic leukemia sustained by bone marrow niche cells. Blood 110(9):3334–3344PubMedCentralPubMedCrossRef
12.
Zhang X, Liu Y, Si YJ et al (2012) Effect of Cx43 gene-modified leukemic bone marrow stromal cells on the regulation of Jurkat cell line in vitro. Leuk Res 36(2):198–204PubMedCrossRef
13.
Nwabo Kamdje AH, Mosna F, Bifari F et al (2011) Notch-3 and Notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrow-derived mesenchymal stromal cells. Blood 118(2):380–389PubMedCrossRef
14.
Yang Y, Mallampati S, Sun B et al (2013) Wnt pathway contributes to the protection by bone marrow stromal cells of acute lymphoblastic leukemia cells and is a potential therapeutic target. Cancer Lett 333:9–17PubMedCrossRef
15.
Silva A, Laranjeira AB, Martins LR et al (2011) IL-7 contributes to the progression of human T-cell acute lymphoblastic leukemias. Cancer Res 71(14):4780–4789PubMedCrossRef
16.
de Vasconcellos JF, Laranjeira AB, Zanchin NI et al (2011) Increased CCL2 and IL-8 in the bone marrow microenvironment in acute lymphoblastic leukemia. Pediatr Blood Cancer 56(4):568–577PubMedCrossRef
17.
Batista A, Barata JT, Raderschall E et al (2011) Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors. Exp Hematol 39(4):457–472 e453PubMedCrossRef
18.
Dosen-Dahl G, Munthe E, Nygren MK, Stubberud H, Hystad ME, Rian E (2008) Bone marrow stroma cells regulate TIEG1 expression in acute lymphoblastic leukemia cells: role of TGFbeta/BMP-6 and TIEG1 in chemotherapy escape. Int J Cancer 123(12):2759–2766PubMedCrossRef
19.
Markovic A, MacKenzie KL, Lock RB (2012) Induction of vascular endothelial growth factor secretion by childhood acute lymphoblastic leukemia cells via the FLT-3 signaling pathway. Mol Cancer Ther 11(1):183–193PubMedCrossRef
20.
Fragoso R, Pereira T, Wu Y, Zhu Z, Cabecadas J, Dias S (2006) VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease. Blood 107(4):1608–1616PubMedCrossRef
21.
Fung KL, Liang RH, Chan GC (2010) Vincristine but not imatinib could suppress mesenchymal niche's support to lymphoid leukemic cells. Leuk Lymphoma 51(3):515–522PubMedCrossRef
22.
Iwamoto S, Mihara K, Downing JR, Pui CH, Campana D (2007) Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 117(4):1049–1057PubMedCentralPubMedCrossRef
23.
Frolova O, Samudio I, Benito JM et al (2012) Regulation of HIF-1alpha signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol Ther 13(10):858–870PubMedCentralPubMedCrossRef
24.
Dong-Feng Z, Ting L, Cheng C et al (2012) Silencing HIF-1alpha reduces the adhesion and secretion functions of acute leukemia hBMSCs. Braz J Med Biol Res 45(10):906–912PubMed
25.
Benito J, Shi Y, Szymanska B et al (2011) Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. PLoS One 6(8):e23108PubMedCentralPubMedCrossRef
26.
Hande KR (1998) Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34(10):1514–1521PubMedCrossRef
27.
Zhu Y, Sun Z, Han Q et al (2009) Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1. Leukemia 23(5):925–933PubMedCrossRef
28.
Warfel NA, El-Deiry WS (2013) p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol 25(1):52–58PubMedCrossRef
29.
Shiu TY, Huang SM, Shih YL, Chu HC, Chang WK, Hsieh TY (2013) Hepatitis C virus core protein down-regulates p21(Waf1/Cip1) and inhibits curcumin-induced apoptosis through microRNA-345 targeting in human hepatoma cells. PLoS One 8(4):e61089PubMedCentralPubMedCrossRef
30.
Ahmad N, Feyes DK, Agarwal R, Mukhtar H (1998) Photodynamic therapy results in induction of WAF1/CIP1/P21 leading to cell cycle arrest and apoptosis. Proc Natl Acad Sci U S A 95(12):6977–6982PubMedCentralPubMedCrossRef
31.
el-Deiry WS, Tokino T, Velculescu VE et al (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75(4):817–825PubMedCrossRef
32.
Mitchell KO, El-Deiry WS (1999) Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells. Cell Growth Differ 10(4):223–230PubMed
33.
Bornstein G, Bloom J, Sitry-Shevah D, Nakayama K, Pagano M, Hershko A (2003) Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J Biol Chem 278(28):25752–25757PubMedCrossRef
34.
Cornils H, Kohler RS, Hergovich A, Hemmings BA (2011) Human NDR kinases control G(1)/S cell cycle transition by directly regulating p21 stability. Mol Cell Biol 31(7):1382–1395PubMedCentralPubMedCrossRef
35.
Drexler HG, Quentmeier H, Dirks WG, Uphoff CC, MacLeod RA (2002) DNA profiling and cytogenetic analysis of cell line WSU-CLL reveal cross-contamination with cell line REH (pre B-ALL). Leukemia 16(9):1868–1870PubMedCrossRef
36.
Zhao YM, Li JY, Lan JP et al (2008) Cell cycle dependent telomere regulation by telomerase in human bone marrow mesenchymal stem cells. Biochem Biophys Res Commun 369(4):1114–1119PubMedCrossRef
37.
Tanaka T, Nakatani T, Kamitani T (2012) Inhibition of NEDD8-conjugation pathway by novel molecules: potential approaches to anticancer therapy. Mol Oncol 6(3):267–275PubMedCrossRef
38.
Chen H, Landen CN, Li Y, Alvarez RD, Tollefsbol TO (2013) Enhancement of cisplatin-mediated apoptosis in ovarian cancer cells through potentiating G2/M arrest and p21 upregulation by combinatorial epigallocatechin gallate and sulforaphane. J Oncol 2013:872957PubMedCentralPubMedCrossRef
39.
Vijayaraghavalu S, Dermawan JK, Cheriyath V, Labhasetwar V (2013) Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest. Mol Pharm 10(1):337–352PubMedCentralPubMedCrossRef
40.
Wu KN, Zhao YM, He Y et al (2014) Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt/mammalian target of rapamycin and extracellular signal-related kinase signaling pathways. Leuk Lymphoma 55(3):668–676PubMedCrossRef
41.
Li Y, Gao Q, Yin G, Ding X, Hao J (2012) WNT/beta-catenin-signaling pathway stimulates the proliferation of cultured adult human Sertoli cells via upregulation of C-myc expression. Reprod Sci 19(11):1232–1240PubMedCrossRef
42.
Pintus G, Tadolini B, Posadino AM et al (2002) Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A down regulates c-myc gene expression and endothelial cell proliferation. Eur J Biochem 269(23):5861–5870PubMedCrossRef
43.
Lanza F, Campioni D, Moretti S et al (2007) Aberrant expression of HLA-DR antigen by bone marrow-derived mesenchymal stromal cells from patients affected by acute lymphoproliferative disorders. Leukemia 21(2):378–381PubMedCrossRef
44.
Campioni D, Lanza F, Moretti S, Ferrari L, Cuneo A et al (2008) Loss of Thy-1 (CD90) antigen expression on mesenchymal stromal cells from hematologic malignancies is induced by in vitro angiogenic stimuli and is associated with peculiar functional and phenotypic characteristics. Cytotherapy 10(1):69–82PubMedCrossRef
Metadata
Title
Bone marrow mesenchymal stromal cells affect the cell cycle arrest effect of genotoxic agents on acute lymphocytic leukemia cells via p21 down-regulation
Authors
Yiran Zhang
Kaimin Hu
Yongxian Hu
Lizhen Liu
Binsheng Wang
He Huang
Publication date
01-09-2014
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 9/2014
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-014-2069-1

Other articles of this Issue 9/2014

Annals of Hematology 9/2014 Go to the issue

Letter to the Editor

Successful treatment of high-risk acute promyelocytic leukemia in very elderly patients using all-trans retinoic acid plus reduced-dose idarubicin

Original Article

FIP1L1 presence in FIP1L1-RARA or FIP1L1-PDGFRA differentially contributes to the pathogenesis of distinct types of leukemia

Letter to the Editor

Is there still a place for itraconazole prophylaxis in high-risk hematology patients?

Original Article

Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function

Original Article

Identification of acquired mutations by whole-genome sequencing in GATA-2 deficiency evolving into myelodysplasia and acute leukemia

Original Article

Determination of accuracy of polycythemia vera diagnoses and use of the JAK2V617F test in the diagnostic scheme
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits